Sponsored

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any sound might reveal vulnerability. When forced to rethink the direction of life and navigate the various treatment options available while bearing the emotional toll of the unknown, it would be understandable to feel overwhelmed. Knowing there’s a clear next step can offer hope, a reason to speak up, and a renewed sense of control. For many, that step could be Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

Sponsored by Regeneron

Watch a webinar as experts on gastrointestinal stromal tumors (GIST) discuss the intricacies of advanced GIST, and the INVICTUS clinical study.

When Bob was first diagnosed and treated for follicular lymphoma, he refused to let the fear of the cancer returning dominate his life. Nearly 25 years later—after having experienced a relapse—Bob is still in remission and chooses to live his life to the fullest and celebrate life’s joys every day.

This episode of the Cancer Horizons podcast features genitourinary oncologist Ulka Vaishampayan, MBBS, and is sponsored by Bristol Myers Squibb.

A new survey from HealthTree Foundation and Adaptive Biotechnologies shows that patients with multiple myeloma report significant clinical and emotional benefits from MRD testing and 90% of patients who have had MRD testing would recommend it to others, underscoring its benefits and providing support for broad clinical use.

Sponsored by AbbVie

This article is sponsored by AstraZeneca and Merck.

A Navy veteran and football coach tackles prostate cancer diagnosis, with family’s support.